Our projects are the cornerstone of our institute, each one crucial to our goal of pioneering discoveries in cancer and aging research. Here, you’ll discover a range of initiatives that challenge the limits of scientific knowledge, offering profound insights into the intricate processes that underpin disease and aging. Spearheaded by eminent researchers, our projects encompass molecular biology, genetics, and cellular studies to forge advancements that promise to revolutionise healthcare. Dive into our portfolio of projects below, where we tirelessly work to unravel the secrets of longevity and cellular health.
Currently Running Projects in IRCAN
-
Identifying candidate drugs in mitochondrial cardiomyopathies: From mouse to human. 2021-2025, AFM-Strategic Project, Partner Véronique Paquis-Flucklinger. The MITODRUG project aims to understand the mechanisms of…
-
Decipher molecular mechanisms responsible for mitochondrial dysfunction leading to motor neuron death. 2022-2025, FRM-Maladies neurodégénératives, PI Véronique Paquis-Flucklinger The project aims to understand the molecular…
-
MITOMICS: an integrative multi-omics approach to decrease diagnosis deadlock of mitochondrial diseases and dissect crosstalk between mtDNA and nuclear genome. 2022-2027, ANR, co-PI Sylvie Bannwarth.…
-
Mitochondrial cristae disorganization and neuroinflammation: a deleterious link leading to neuronal death. 2024-2026, FRM-Maladies neurodégénératives, PI Sylvie Bannwarth Our project seeks to explore molecular mechanisms…
-
MIM-IR: Characterization of the links between inner mitochondrial membrane homeostasis and interferon signaling. 2025-2027, ANR, PI Sylvie Bannwarth Mitochondrial cristae disorganization can lead to mitochondrial…
-
MitoCOSMIC: Loss of mitochondrial cristae structure in motor neuron disease: mechanistic and therapeutic approaches. 2025-2027, ANR Our results suggest that a mitochondrial transport defect along…
-
Duration: 2023 – 2026 Funding agency: Nice University Hospital Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy. Interferon Alfa therapy offers a promising…
-
Duration: 2022 – 2024 Funding agency: Nice University Hospital, French Rare Disease ORKID Network Membranous nephropathy (MN) is a kidney disorder that can lead to…
-
Duration: 2020 – ongoing Funding agency: CD06 In response to the unprecedented global pandemic, our team has launched an in-depth study to analyze the immune…
-
Duration: 2020 – 2025 Funding agency: National Clinical Research Program (PHRC 2017) Personalized Medicine in Membranous Nephropathy: Epitope spreading in MN patients, consisting of the…